160 related articles for article (PubMed ID: 15540536)
21. [Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis].
Paquot N; Tappy L
Rev Med Liege; 2005; 60(5-6):369-73. PubMed ID: 16035296
[TBL] [Abstract][Full Text] [Related]
22. Metabolic syndrome: a work in progress, but a useful construct.
Beaser RS; Levy P
Circulation; 2007 Apr; 115(13):1812-8; discussion 1818. PubMed ID: 17404172
[No Abstract] [Full Text] [Related]
23. Plasma adiponectin levels are related to obesity, inflammation, blood lipids and insulin in type 2 diabetic and non-diabetic Trinidadians.
Nayak BS; Ramsingh D; Gooding S; Legall G; Bissram S; Mohammed A; Raychaudhuri A; Sahadeo B; Pandohie V; Figaro K
Prim Care Diabetes; 2010 Oct; 4(3):187-92. PubMed ID: 20580627
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of insulin on endothelial function, inflammation, and atherogenesis and their implications.
Kuritzky L; Nelson SE
J Fam Pract; 2005 Jun; 54(6):S7-9. PubMed ID: 16021783
[No Abstract] [Full Text] [Related]
25. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus.
Daniele G; Guardado Mendoza R; Winnier D; Fiorentino TV; Pengou Z; Cornell J; Andreozzi F; Jenkinson C; Cersosimo E; Federici M; Tripathy D; Folli F
Acta Diabetol; 2014 Feb; 51(1):123-31. PubMed ID: 24370923
[TBL] [Abstract][Full Text] [Related]
26. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
van Tits LJ; Arioglu-Oral E; Sweep CG; Smits P; Stalenhoef AF; Tack CJ
Neth J Med; 2005; 63(7):250-5. PubMed ID: 16093575
[TBL] [Abstract][Full Text] [Related]
28. The endothelium and vascular inflammation in diabetes.
Hartge MM; Unger T; Kintscher U
Diab Vasc Dis Res; 2007 Jun; 4(2):84-8. PubMed ID: 17654441
[TBL] [Abstract][Full Text] [Related]
29. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus.
Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Ampatzidis G; Liapis CD; Alevizos M
Eur J Cardiovasc Prev Rehabil; 2007 Dec; 14(6):837-43. PubMed ID: 18043308
[TBL] [Abstract][Full Text] [Related]
30. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
31. Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance.
Oberbach A; Tönjes A; Klöting N; Fasshauer M; Kratzsch J; Busse MW; Paschke R; Stumvoll M; Blüher M
Eur J Endocrinol; 2006 Apr; 154(4):577-85. PubMed ID: 16556721
[TBL] [Abstract][Full Text] [Related]
32. Treatment of metabolic syndrome.
Wagh A; Stone NJ
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
[TBL] [Abstract][Full Text] [Related]
33. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
34. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
Viberti G
J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
[TBL] [Abstract][Full Text] [Related]
35. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients.
Kopp HP; Kopp CW; Festa A; Krzyzanowska K; Kriwanek S; Minar E; Roka R; Schernthaner G
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1042-7. PubMed ID: 12714437
[TBL] [Abstract][Full Text] [Related]
36. [Secretory activity of the adipocytes and comorbidities of obesity].
Skurk T; Hauner H
MMW Fortschr Med; 2005 Jan; 147(4):41-3. PubMed ID: 15745341
[TBL] [Abstract][Full Text] [Related]
37. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.
Blüher M; Fasshauer M; Tönjes A; Kratzsch J; Schön MR; Paschke R
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):534-7. PubMed ID: 16235156
[TBL] [Abstract][Full Text] [Related]
38. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
39. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
[TBL] [Abstract][Full Text] [Related]
40. Pre-diabetes, insulin resistance, inflammation and CVD risk.
Haffner SM
Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S9-S18. PubMed ID: 12880690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
